A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

NCT06211179 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Treatment A: Mavacamten intact oral capsule
DRUG: Treatment B: Mavacamten open capsule in suspension
DRUG: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)

Sponsor

Bristol-Myers Squibb